View
792
Download
1
Category
Tags:
Preview:
DESCRIPTION
AEMD Aethlon Medical July Investor PowerPoint Presentation used at RedChip's 2010 NY Midsummer Elite Equities Conference.
Citation preview
JIM JOYCECHAIRMAN, CEO
REDCHIP EQUITIES CONFERENCENASDAQ MARKETPLACE
July 21, 2010
MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW. SEC.GOV.
Forward looking statements
IF YOU HAVE CANCER…………
CREATING REVOLUTIONARY DEVICESTHAT ADDRESS INFECTIOUS DISEASE& CANCER
CHANGE THE WAY PEOPLE THINK ABOUT TREATING INFECTIOUS DISEASE & CANCER
THE FIRST MEDICAL DEVICE TO SELECTIVELY FILTER VIRUSES AND IMMUNOSUPPRESSIVE PARTICLES FROM CIRCULATION
THE HEMOPURIFIER®
Leveraging Established Infrastructure
Selectively Targets the Removal of:
The Most Advanced Broad-Spectrum Countermeasure
Bioterror & Pandemic Threats
Virus CollaboratorsHuman Variety
Ebola CDC / USAMRIID YES
Dengue NIV / WHO YES
Lassa SFBR YES
West Nile Battelle YES
H5N1 Avian Battelle YES
Spanish Flu of 1918-R Battelle YES
2009 H1N1 Swine Battelle YES
Monkey pox Battelle NO
OUR HEMOPURIFIER® IS THEONLY TREATMENT STRATEGY TO ADDRESS DRUG RESISTANT AIDS PATIENTS
Human Immunodeficiency Virus (HIV)
DO HIV INFECTED INDIVIDUALS HAVE TO DIE WHEN THEY NO LONGER RESPOND TO THEIR MEDS?
IN THE ABSENCE OF DRUG THERAPY
HIV/AIDS Patient Data
92% reduction of viral load Improved CD4+ T-cell %
30 DAY STUDY – THREE HEMOPURIFIER® TREATMENTS PER WEEK
AIDS
TO ACCELERATE EARLY VIRAL LOAD REDUCTION OF HCV STANDARD OF CARE (SOC) DRUG THERAPY
Hepatitis-C Virus (HCV)
CAN SELECTIVE VIRAL FILTRATION IMPROVE HCV CURE RATES?
IN THE ABSENCE OF DRUG THERAPY
5 Day HCV Treatment Studies
ONE WEEK STUDY – THREE HEMOPURIFIER® TREATMENTS
Validation for Viral Filtration Therapy
Success %
HEMOPURIFIER®+ TELAPRIVIR+ INTERFERON-RIBAVIRIN (SOC)= ____% SVR?
An Enduring Adjunct Opportunity
Hemopurifier® + Current SOC Hemopurifier® + Future Iterations
of SOC 65 drugs in competition
IF YOU HAVE CANCER…………
EXOSOMES ARE SECRETED BY ALL TUMORS, LYMPHOMAS, & LEUKEMIAS
Exosomes are Immunosuppressive
Induce Apoptosis Disrupt T-Cell Signaling Inhibit Cytokine Production Angiogenesis Metastasis
Tumor-Secreted Exosomes
WE ARE AT THE FOREFRONT OF THE EMERGING CANCER EXOSOME FIELD
Full-Spectrum Cancer Opportunity
ARE EXOSOMES PRESENT?
Diagnosis of Cancer
WHAT QUANTITY OF EXOSOMES ARE PRESENT IN BLOOD?
Monitoring Cancer Progression
Enzyme Linked Lectin Specific Assay
ELLSA
REMOVE THE PRESENCE OF IMMUNOSUPPRESSIVE EXOSOMES
Cancer Therapy
OUR HEMOPURIFIER® IS THE SOLE THERAPEUTIC STRATEGY TO ADDRESS IMMUNSUPPRESSIVE EXOSOMES
MAXIMIZING THE ABILITY OF THE IMMUNE SYSTEM TO COMBAT CANCER?
A Complementary Therapeutic
Targets Benefit w/o Stacking additional drug
toxicity Adding drug interaction risk
DOES THE MEDICAL COMMUNITY HAVE INTEREST IN EXOSOMES?
Interest in Exosomes
DOES THE MEDICAL COMMUNITY HAVE INTEREST IN AETHLON MEDICAL?
>600
Push vs. Pull
ADVANCING COLLABORATIVE RELATIONSHIPS WITH THOUGHT LEADERS REPRESENTING PREMIER CANCER TREATMENT INSTITUTES
A Foundation to Build Value
www.npr.org/templates/story/story.php?storyId=128339775
Guidance DisclosureRemainder of 2010
Remainder of 2010 Guidance
Infectious Disease Initiate Medanta-Medicity HCV
adjunct treatment studies (establish revenue stream)
Increase treatment site opportunities Define clinical plans beyond India
Cancer Data from multiple studies
Hemopurifier® & ELLSA Disclosure of collaborative partners Define U.S. clinical programs
CREATING REVOLUTIONARY DEVICESTHAT ADDRESS INFECTIOUS DISEASE& CANCER
CHANGE THE WAY PEOPLE THINK ABOUT TREATING INFECTIOUS DISEASE & CANCER
AEMD
JIM JOYCECHAIRMAN, CEO
8910 UNIVERSITY CENTER LANESAN DIEGO, CA. 92122
JJ@AETHLONMEDICAL.COM858.459.7800 X301
ASSISTANT: CHARLENE OWENCOWEN@AETHLONMEDICAL.COM858.459.7800 X305
Recommended